Skip to main content
. Author manuscript; available in PMC: 2007 Nov 13.
Published in final edited form as: Pain. 2007 Feb 2;131(1-2):83–95. doi: 10.1016/j.pain.2006.12.018

Figure 7. Intra-RVM delivery of the selective Y1 receptor antagonist BIBO3304 reverses the effects of NPY in the PSNL model.

Figure 7

When administered 15 min before NPY (1 μg), the unilateral microinjection BIBO (1 μg) but not saline prevented the anti-allodynic (Panels A–B) and anti-hyperalgesic (Panels C–D) effects of NPY at the hindpaw ipsilateral to nerve injury. BIBO had no effect when administered alone. Numbers of animals in each group are in parenthesis. Error bars = SEM. ★ P<0.05 vs saline, *P<0.05 vs NPY alone, Mann-Whitney U test subsequent to Kruskal Wallis or post-hoc Bonferroni subsequent to ANOVA.